Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Belimumab in Persistent Immune Thrombocytopenia
NCT03154385Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab in immune thrombocytopenia (ITP), sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2017; status: completed.
02
Drugs
belimumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03154385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154385.